Cat. No. | Product name | CAS No. |
DC66489 |
CB1 agonist 1
Featured
CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders. |
851212-80-1 |
DC66490 |
CK2-IN-4
Featured
CK2-IN-4 (compound 5) is a protein kinase (CK2) inhibitor (IC50=8.6 µM). CK2-IN-4 has good potential for research in the areas of cancer, viral infections and glomerulonephritis. |
313985-59-0 |
DC66491 | BCR-ABL-IN-7 Featured | 688050-42-2 |
DC66492 |
Tyrosine kinase-IN-7
Featured
Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively. |
345615-74-9 |
DC66493 |
JY-2
Featured
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity. |
339103-05-8 |
DC66494 |
Casein kinase 1δ-IN-14
Featured
Casein kinase 1δ-IN-14 (compound 481) is a casein kinase inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease. |
793722-88-0 |
DC66495 |
ROS kinases-IN-2
Featured
ROS kinases-IN-2 is a ROS kinase inhibitor with 21.53% inhibition at 10 μM. |
687576-28-9 |
DC66496 |
HIF-PHD-IN-3
Featured
HIF-PHD-IN-3 (compound 4) is a potent hiPSC-CM cardioprotective scaffold. HIF-PHD-IN-3 can induce upregulation of heme oxygenase-1. |
794582-71-1 |
DC66497 | Clevidipine Impurity 39 Featured | 167221-70-7 |
DC66498 | 5-Phenyl-1H-indole Featured | 66616-72-6 |
DC66499 | 4-Isopropylbenzoyl chloride Featured | 21900-62-9 |
DC66500 |
OTUB2-IN-1
Featured
OTUB2-IN-1, a specific inhibitor of OTUB2 (KD: ~12 μM), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) . |
|
DC66501 |
N-Acetylcysteine amide
Featured
N-Acetylcysteine amide is a cell membranes and blood brain barrier permeant thiol antioxidant and neuroprotective agent, reduces ROS production. |
38520-57-9 |
DC66502 | Ethyl 2-(4-hydroxyphenyl)-2-oxoacetate Featured | 70080-54-5 |
DC66503 | Boc-DL-leucine Featured | 64727-35-1 |
DC66504 | N-Boc-3-Iodo-L-alanine benzyl ester Featured | 108957-20-6 |
DC66505 | trans-Glutaconic acid Featured | 1724-02-3 |
DC66506 | Naphthalene, 2-phenyl- Featured | 612-94-2 |
DC66507 | (1H-benzodimidazol-2-yl)methanamine hydrochloride Featured | 7757-21-3 |
DC26111 |
Cevidoplenib
Featured
Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC50s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively. |
1703788-21-9 |
DC66508 |
BP Lipid 222
Featured
BP Lipid 222 BP Lipid 222 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315 (BP-25498). The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries. |
|
DC66509 |
BP Lipid 211
Featured
BP Lipid 211 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. Both ester bonds are located at C10 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose. |